Pfizer has officially registered a Phase III clinical trial for SGN-PDL1V, an antibody-drug conjugate (ADC) targeting PD-L1, on the Clinicaltrials.gov website. This trial is specifically designed for patients with PD-L1-positive non-small cell lung cancer who have not responded to PD-1 treatment and harbor EGFR or ALK mutations. The study aims to enroll 680 patients and is anticipated to conclude by early 2028.

Early results from the Phase I trial of SGN-PDL1V have been promising, revealing an objective response rate of 27.3% with an average duration of response of 7.9 months. Furthermore, the drug has demonstrated manageable side effects. PD-L1 ADC drugs are highly anticipated due to their dual mechanism that combines targeted toxin delivery for cancer cell killing with the relief of immune suppression, offering broad therapeutic potential.

In China, HLX43, developed by Fuhong Hanlin and utilizing TMALIN® technology, has also progressed to Phase II clinical trials. This ADC has shown promising antitumor activity and safety, further underscoring the growing interest and progress in this therapeutic area.